Abstract: A method of treatment or prophylaxis of angina in mammals, such as humans, which comprises the administration to the sufferer of an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a solvate of any of the foregoing: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, A and B are herein defined.

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof; ##STR1## wherein: R.sub.1 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or halogen;R.sub.2 and R.sub.3 are both hydrogen or together represent a bond;R.sub.4 is hydrogen and R.sub.5 is hydrogen or R.sub.4 and R.sub.5 together represent an oxo group;R.sub.6 is C.sub.1-7 alkyl substituted by NR.sub.8 R.sub.9 where R.sub.8 and R.sub.9 are independently hydrogen or C.sub.1-4 alkyl or together are C.sub.3-7 polymethylene optionally containing a further heteroatom which is oxygen, sulphur or nitrogen substituted by R.sub.10 where R.sub.10 is hydrogen, C.sub.1-4 alkyl or benzyl, and optionally substituted by one or two C.sub.1-4 alkyl, C.sub.2-5 alkanoyl, C.sub.1-4 alkoxycarbonyl, aminocarbonyl optionally substituted by one or two C.sub.1-6 alkyl groups or by a benzyl group, cyano, phenyl or benzyl and wherein any phenyl or benzyl group is optionally substituted in the phenyl ring by one or two halo, CF.sub.3, C.sub.1-4 alkyl, C.sub.

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein: R.sub.1 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or halogen;R.sub.2 and R.sub.3 are both hydrogen or together represent a bond;R.sub.4 is selected from C.sub.1-6 alkyl, phenyl, phenyl C.sub.1-4 alkyl, COR.sub.8 where R.sub.8 is hydroxy, C.sub.1-6 alkoxy or NR.sub.9 R.sub.10 where R.sub.9 and R.sub.10 are independently hydrogen or C.sub.1-4 alkyl and CH.sub.2 OR.sub.11 and R.sub.11 is hydrogen, C.sub.1-4 alkyl or C.sub.1-4 alkanoyl;R.sub.5 is hydrogen, C.sub.1-6 alkyl or phenyl C.sub.1-4 alkyl;R.sub.6 is phenyl C.sub.1-7 alkyl in which the phenyl moiety is optionally substituted by one or two of halogen, ortho-nitro, meta- or para-methoxy, methyl or NR.sub.12 R.sub.13 wherein R.sub.12 and R.sub.13 are independently hydrogen or C.sub.1-6 alkyl or R.sub.12 and R.sub.13 together are C.sub.2-6 polymethylene or the phenyl moiety is 3,4-disubstituted by methylenedioxy or ethylenedioxy; andR.sub.7 is hydrogen or C.sub.

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein: R.sub.1 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or halogen;R.sub.2 and R.sub.3 are both hydrogen or together represent a bond;R.sub.4 is hydrogen and R.sub.5 is hydrogen or R.sub.4 and R.sub.5 together represent an oxo group;R.sub.6 is phenyl, phenyl C.sub.1-7 alkyl or phenyl C.sub.1 -7 alkanoyl, in which the phenyl moiety is substituted by NR.sub.8 R.sub.9 wherein R.sub.8 is C.sub.1-6 alkyl substituted by a group R.sub.10 selected from hydroxy, halo, CF.sub.3 or COR.sub.11 where R.sub.11 is hydroxy, C.sub.1-4 alkoxy or amino optionally substituted by one or two C.sub.1-4 alkyl groups, and R.sub.9 is hydrogen, C.sub.1-6 alkyl or R.sub.8 ; andR.sub.7 is hydrogen or C.sub.1-4 alkyl.

Abstract: A compound of the formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein: R.sub.1 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or halogen;R.sub.2 and R.sub.3 are both hydrogen or together represent a bond;R.sub.4 is hydrogen and R.sub.5 is hydrogen or R.sub.4 and R.sub.5 together represent an oxo group;R.sub.6 is C.sub.1-7 alkyl substituted by NR.sub.8 R.sub.9 where R.sub.8 and R.sub.9 are independently hydrogen or C.sub.1-4 alkyl or together are C.sub.3-7 polymethylene optionally containing a further hetereoatom which is oxygen, sulphur or nitrogen substituted by R.sub.10 where R.sub.10 is hydrogen, C.sub.1-4 alkyl or benzyl, and optionally substituted by one or two C.sub.1-4 alkyl, C.sub.2-5 alkanoyl, C.sub.1-4 alkoxycarbonyl, aminocarbonyl optionally substituted by one or two C.sub.1-6 alkyl groups or by a benzyl group, cyano, phenyl or benzyl and wherein any phenyl or benzyl group is optionally substituted in the phenyl ring by one or two halo, CF.sub.3, C.sub.1-4 alkyl, C.sub.

Abstract: A method for the treatment of cerebral vascular and neuronal degenerative disorders associated with learning, memory and cognitive dysfunctions including cerebral senility, multi-infarct dementia and senile dementia of the Alzheimer type and/or peripheral vascular disease and/or proliferative skin disease in mammals, such as humans, which comprises administering to the mammal in need of such treatment an effective amount of 1,3-di-n-butyl-7-(2-oxypropyl) xanthine or a pharmaceutically acceptable salt thereof.

Abstract: A method for the treatment and/or prophylaxis of cerebrovascular disorders and/or disorders associated with cerebral senility in mammals, such as humans, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective and/or prophylactic amount of a compound of formula (I): ##STR1## wherein (i) R.sub.1 is a group --X--CO--CH.sub.3 where X is a hydrocarbon radical having up to 4 carbon atoms which may be substituted by a methyl group,R.sub.2 and R.sub.3, which may be the same or different, each represents a straight-chain or branched-chain alkyl radical of 2 to 6 carbon atoms, or a cyclohexyl, alkoxyalkyl or hydroxyalkyl radical, andY and Z each represent oxygen;(ii) R.sub.1 is a group --CH.sub.2 (OR.sub.4)(OR.sub.5)CH.sub.3 wherein R.sub.4 is an alkyl radical of 1 to 4 carbon atoms and R.sub.5 is an alkyl radical of 1 to 4 carbon atoms or R.sub.4 is linked to R.sub.5 so that the OR.sub.4 and OR.sub.

Abstract: Compounds of the formula (I): ##STR1## and pharmaceutically acceptable acid addition salts thereof, wherein,Ar is optionally substituted phenyl or naphthyl, or pyridyl;E is O, S or a bond;R.sub.5 is hydrogen, andJ is C.sub.3-5 polymethylene, optionally substituted by one or two groups selected from methyl or optionally derivatized hydroxy; orAr and R.sub.5 together form a group ##STR2## where Ar.sup.1 is optionally substituted 1,2-phenylene;Z is O or CH.sub.2, andm is 0 or 1, when E is O or S, or 1 when E is bond;R.sub.1 is hydrogen, C.sub.1-4 alkyl optionally substituted phenyl; C.sub.3-8 alkanoyl, or phenyl C.sub.2-8 alkanoyl, any phenyl moiety being optionally substituted; a group COR.sub.2 where R.sub.2 is C.sub.2-3 alkoxy, phenyl C.sub.1-4 alkoxy, the phenyl moiety being optionally substituted, or C.sub.1-4 alkoxy C.sub.3-4 alkoxy; or a group CXNHR.sub.3 where X is O or S and R.sub.3 is C.sub.2-4 alkyl, C.sub.2-4 alkenyl, phenyl or phenyl C.sub.

Abstract: Compounds of the formula (I) and salts thereof: ##STR1## wherein: A is a bond, --CH.sub.2 -- or --CH.dbd.CH--;R.sup.2 is hydrogen and R.sup.1 is selected from C.sub.1-4 alkyl, hydroxyl, C.sub.1-4 alkoxy, C.sub.1-4 alkanoyloxy, hydrogen, halogen, nitro, cyano, and amino optionally substituted by one or two C.sub.1-4 alkyl groups or by C.sub.1-4 alkanoyl;R.sup.4 is C.sub.1-4 alkyl, hydroxy, C.sub.1-4 alkoxy, C.sub.1-4 alkanoyloxy or nitrato;R.sub.2 N is 1-piperidyl, morpholino or 4-methyl-1-piperazyl, optionally substituted by one or two methyl groups in the 2-, 4- or 6- positions as apt, or 1-pyrrolidyl substituted by one or two methyl groups.m is 0 or 1; andn is 0 to 3a process for their preparation and compositions containing them.